Drug Profile
Research programme: triple reuptake inhibitors - AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mayo Clinic; Virginia Tech Intellectual Properties
- Developer AstraZeneca Pharmaceuticals
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 09 Feb 2009 Preclinical trials in Depression in USA (unspecified route)